InicioPRE • NASDAQ
add
Prenetics Global Ltd
4,42 $
Después del cierre:(5,20 %)+0,23
4,65 $
Cerrados: 22 nov, 20:00:00 GMT-5 · USD · NASDAQ · Renuncia de responsabilidad
Cierre anterior
4,61 $
Intervalo diario
4,42 $ - 4,42 $
Intervalo anual
2,85 $ - 7,84 $
Cap. bursátil
54,00 M USD
Volumen medio
11,72 mil
Relación precio-beneficio
-
Rentabilidad por dividendo
-
Bolsa de valores principal
NASDAQ
Noticias sobre los mercados
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
(USD) | jun 2024info | Cambio interanual |
---|---|---|
Ingresos | 5,94 M | 4,32 % |
Gastos operativos | 14,38 M | 0,52 % |
Ingresos netos | -10,72 M | 50,83 % |
Margen de beneficio neto | -180,46 | 52,87 % |
Beneficios por acción | — | — |
EBITDA | -9,51 M | 13,59 % |
Tipo impositivo efectivo | 0,79 % | — |
Balance general
Activos totales
Responsabilidades totales
(USD) | jun 2024info | Cambio interanual |
---|---|---|
Efectivo y a corto plazo | 63,89 M | -67,46 % |
Activos totales | 233,31 M | -16,93 % |
Responsabilidades totales | 42,30 M | -30,22 % |
Patrimonio total | 191,00 M | — |
Acciones en circulación | 12,22 M | — |
Precio-valor contable | 0,30 | — |
Rentabilidad económica | -11,12 % | — |
Retorno sobre capital | -13,33 % | — |
Flujo de caja
Variación neta del flujo de caja
(USD) | jun 2024info | Cambio interanual |
---|---|---|
Ingresos netos | -10,72 M | 50,83 % |
Efectivo de operaciones | — | — |
Efectivo de inversión | — | — |
Efectivo de financiación | — | — |
Variación neta del flujo de caja | — | — |
Flujo de caja libre | — | — |
Información sobre la empresa
Prenetics is a health sciences company headquartered in Hong Kong with a significant presence in the United States. It is best known for its innovations in consumer and clinical health, focusing on early detection, prevention, and treatment of diseases, particularly cancer.
Prenetics' consumer initiatives are spearheaded by IM8, a health and wellness brand. Another key offering is CircleDNA, which utilizes next-generation sequencing technology to provide comprehensive DNA testing for consumers, offering insights into health, wellness, and genetic predispositions.
The company's clinical arm includes Insighta, a joint venture focused on developing multi-cancer early detection technologies. Additionally, ACT Genomics develops and provides a variety of genomic profiling panels, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests, tailored to meet specific clinical needs. ACTLiquid Pro, a sequencing-based liquid biopsy assay, and ACTMonitor, which tracks drug resistance, treatment response, and cancer recurrence in real-time, are among its notable products. ACT Risk offers management solutions for assessing and mitigating cancer risks. Wikipedia
Fundación
2014
Sitio web
Empleados
322